Lipocine (LPCN) News Today → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free LPCN Stock Alerts $6.92 -0.01 (-0.14%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29 at 4:12 AM | americanbankingnews.comLipocine (NASDAQ:LPCN) Shares Pass Above 50 Day Moving Average of $5.29May 28, 2024 | investorplace.com7 Penny Biotech Stocks to Triple Your InvestmentMay 9, 2024 | investorplace.comLPCN Stock Earnings: Lipocine Beats EPS for Q1 2024May 9, 2024 | finance.yahoo.comLipocine Announces Financial Results for the First Quarter Ended March 31, 2024May 8, 2024 | prnewswire.comLipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024May 1, 2024 | prnewswire.comLipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154April 12, 2024 | msn.comLipocine hopes obesity drug could boost muscle mass in combo with GLP1-RAsApril 11, 2024 | finanznachrichten.deLipocine Inc.: Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityApril 11, 2024 | fr.investing.comLipocine annonce les résultats positifs d'une étude sur le traitement de l'obésitéApril 11, 2024 | markets.businessinsider.comLipocine Reports Positive Phase 2 Results For LPCN 2401 In Participants With ObesityApril 11, 2024 | finance.yahoo.comLipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityApril 11, 2024 | prnewswire.comLipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityMarch 28, 2024 | finanznachrichten.deLipocine Inc.: Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisMarch 28, 2024 | markets.businessinsider.comLipocine: LPCN 1148 Meets Primary And Hepatic Encephalopathy Endpoints In Phase 2 StudyMarch 28, 2024 | prnewswire.comLipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisMarch 25, 2024 | finance.yahoo.comCirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsightMarch 25, 2024 | prnewswire.comLipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154March 7, 2024 | investorplace.comLPCN Stock Earnings: Lipocine Beats EPS for Q4 2023March 7, 2024 | seekingalpha.comLipocine GAAP EPS of -$3.14March 7, 2024 | prnewswire.comLipocine Announces Financial Results for the Full Year Ended December 31, 2023March 6, 2024 | finance.yahoo.comLipocine to Present at 36th Annual Roth ConferenceFebruary 6, 2024 | finance.yahoo.comLipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154February 2, 2024 | finanznachrichten.deLipocine Inc.: Lipocine Announces Continued Commercialization of TLANDO through Verity PharmaceuticalsFebruary 2, 2024 | fr.investing.comLipocine transfère la commercialisation de TLANDO à Verity PharmaFebruary 2, 2024 | finance.yahoo.comLipocine Announces Continued Commercialization of TLANDO® through Verity PharmaceuticalsJanuary 18, 2024 | marketwatch.comLipocine Shares Rise Premarket on Tlando Licensing DealJanuary 18, 2024 | msn.comLipocine licenses Tlando testosterone therapy to Verity PharmaJanuary 18, 2024 | markets.businessinsider.comLipocine Signs TLANDO Franchise License Deal With Verity PharmaJanuary 18, 2024 | finance.yahoo.comLipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and CanadaDecember 19, 2023 | finance.yahoo.comLipocine to Present at Biotech Showcase 2024November 22, 2023 | msn.comLipocine files for $150M mixed shelfNovember 13, 2023 | marketwatch.comLipocine to Share Cirrhosis Treatment LPCN 1148 Results at The Liver MeetingNovember 13, 2023 | finance.yahoo.comLipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023November 10, 2023 | markets.businessinsider.comBuy Rating for Lipocine: Anticipation of Successful LPCN 1154 Study and Strong Financial PositionNovember 8, 2023 | finance.yahoo.comLipocine Announces Financial Results for the Third Quarter Ended September 30, 2023November 5, 2023 | morningstar.comLipocine Inc LPCNNovember 1, 2023 | finance.yahoo.comLipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023October 26, 2023 | finance.yahoo.comLipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum DepressionOctober 23, 2023 | finance.yahoo.comLipocine to Present at the H.C. Wainwright Annual NASH Investor ConferenceSeptember 19, 2023 | finance.yahoo.comLipocine to Present at the Cantor Fitzgerald Global Healthcare ConferenceAugust 17, 2023 | stocknews.comLooking for a Value Investment? Check out These 3 Pharma StocksAugust 16, 2023 | finance.yahoo.comLPCN: Trial Results Improve OutlookAugust 10, 2023 | finance.yahoo.comLipocine Announces Financial Results for the Second Quarter Ended June 30, 2023July 31, 2023 | finance.yahoo.comLPCN: 1148 Shows Muscle Loss ReversalJuly 27, 2023 | benzinga.comWhy Lipocine Stock Is Moving Higher Today?July 27, 2023 | investorplace.comWhy Is Lipocine (LPCN) Stock Up 32% Today?June 14, 2023 | finance.yahoo.comLipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual ConferenceJune 7, 2023 | finance.yahoo.comLipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023May 16, 2023 | msn.comLipocine stock dips after bridging study data of LPCN 1154 for postpartum depressionMay 16, 2023 | finance.yahoo.comPositive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression Get Lipocine News Delivered to You Automatically Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter. Email Address ‘America’s Top Trader’ Who Predicted the Biggest Financial Events of The Last 30 Years, Issues New Warning… (Ad)Eric Fry has called every major market-event of the last 30 years... Also, recommending 41 stocks – with EACH one surging for 1,000%+ returns... Eric is releasing his biggest WARNING of 2024 LPCN Media Mentions By Week LPCN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LPCN News Sentiment▼1.110.81▲Average Medical News Sentiment LPCN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LPCN Articles This Week▼30▲LPCN Articles Average Week Get Lipocine News Delivered to You Automatically Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TNXP News ORGS News LPTX News LTRN News MCRB News IMAB News CTMX News RPTX News SCPH News GOSS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LPCN) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyOn June 10, Nvidia makes its next big moveWeiss RatingsMAJOR BUY SIGNAL: Move Fast, Washington/Pelosi/Mill…AltimetryUnlock Explosive Gains with This Defense StockBehind the MarketsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin Pro Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
